We can enhance the anti-tumour capacities of neutrophils by interfering with innate immune inhibitory checkpoints to restore antibody-mediated anti-tumour activities, by targeting proteins downstream of the inhibitory receptor, by using IgA-based therapeutic mAbs that bind to the activating Fc receptors, and by modifying the Fc region of IgG therapeutic antibodies that increases affinity to Fc receptors, as shown in Figure 6 (53). Here, CD79A is linked to neoplasm.